Drugs / Probiatop
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT05603403 | Oct 2022 → Mar 2023 | digestive system disorder | Azidus Brasil | Completed | No outcome recorded |
| Phase 4 | NCT02519556 | Aug 2015 → Aug 2016 | atopic eczema | Casa Espirita Terra de Ismael | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Probiatop | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02519556 ↗ |
| Modality | Other / unclassified | “mixture of probiotics (Lactobacillus and Bifidobacterium)” NCT02519556 ↗ |
| Route | Oral | “take it in every morning” NCT02519556 ↗ |